JP2014504588A - 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト - Google Patents

膵島細胞移植のためのｇｌｐ−１受容体アゴニスト Download PDF

Info

Publication number
JP2014504588A
JP2014504588A JP2013546337A JP2013546337A JP2014504588A JP 2014504588 A JP2014504588 A JP 2014504588A JP 2013546337 A JP2013546337 A JP 2013546337A JP 2013546337 A JP2013546337 A JP 2013546337A JP 2014504588 A JP2014504588 A JP 2014504588A
Authority
JP
Japan
Prior art keywords
glp
receptor agonist
patient
transplantation
agonist compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013546337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504588A5 (https=
Inventor
クワメ・オセイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of JP2014504588A publication Critical patent/JP2014504588A/ja
Publication of JP2014504588A5 publication Critical patent/JP2014504588A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013546337A 2010-12-22 2011-12-20 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト Pending JP2014504588A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426076P 2010-12-22 2010-12-22
US61/426,076 2010-12-22
PCT/US2011/066251 WO2012088157A2 (en) 2010-12-22 2011-12-20 Glp-1 receptor agonists for islet cell transplantation

Publications (2)

Publication Number Publication Date
JP2014504588A true JP2014504588A (ja) 2014-02-24
JP2014504588A5 JP2014504588A5 (https=) 2015-01-22

Family

ID=46314852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013546337A Pending JP2014504588A (ja) 2010-12-22 2011-12-20 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト

Country Status (4)

Country Link
US (1) US9161953B2 (https=)
EP (1) EP2654767A4 (https=)
JP (1) JP2014504588A (https=)
WO (1) WO2012088157A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9974651B2 (en) * 2015-02-05 2018-05-22 Mitral Tech Ltd. Prosthetic valve with axially-sliding frames
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN107569678B (zh) * 2017-08-31 2020-10-30 华中科技大学同济医学院附属同济医院 利拉鲁肽在制备治疗急慢性移植排斥反应药物中的应用
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
KR102352336B1 (ko) * 2020-07-10 2022-01-19 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 융합단백질 및 이의 용도
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015664A1 (en) * 2008-08-06 2010-02-11 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
EP0996459B1 (en) 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
AU2373400A (en) 1998-12-22 2000-07-12 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20010046489A1 (en) * 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
CA2396157A1 (en) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
WO2006117221A1 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015664A1 (en) * 2008-08-06 2010-02-11 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES COMMUN., 2008, 367(4), P.793-798, JPN6015041124, ISSN: 0003174332 *
DIABETES, 2009, 58(SUPPL.1), ABSTRACT NO, 1957-P, JPN6015041130, ISSN: 0003174335 *
DIABETES, JUNE 2010, 57(SUPPL.1), ABSTRACT NO, 141-OR, JPN6015041127, ISSN: 0003174334 *
移植, 2008, 43(3), P.229, S-6, JPN6015041125, ISSN: 0003174333 *

Also Published As

Publication number Publication date
EP2654767A2 (en) 2013-10-30
EP2654767A4 (en) 2014-05-21
WO2012088157A3 (en) 2012-08-23
WO2012088157A2 (en) 2012-06-28
US9161953B2 (en) 2015-10-20
US20140017208A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
US9161953B2 (en) GLP-1 receptor agonists for islet cell transplantation
US10941187B2 (en) GLP-1, exendin-4, peptide analogs and uses thereof
EP2496249B1 (en) Glp-1 receptor agonist for use in treating obstructive sleep apnea
RU2442792C2 (ru) Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
ES2320754T3 (es) Tratamiento de la diabetes.
DE60317554T2 (de) Gastrin-zusamemsetzungen und-formulierungen und verfahren zur verwendung und herstellung
US20090202494A1 (en) Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
JP2009291206A (ja) ＧＬＰ−１またはＥｘｅｎｄｉｎ−４による、非インスリン産生細胞のインスリン産生細胞への分化、およびその使用
JP2006506386A5 (https=)
EP2435061A1 (en) Glp-1 receptor agonist compounds for sleep enhancement
Triplitt et al. Incretin Mimetics and Dipeptidyl Peptidase‐IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus
WO2007062531A1 (en) Combination treatments with gastrin agonists for diabetes and related diseases
CN1938334A (zh) Glp－1激动剂和胃泌素化合物的联合使用
Crutchlow et al. Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice
George Future trends in diabetes management.
US20060009516A1 (en) Use of ingap for reversing diabetes
JPH06219963A (ja) ｒｅｇタンパク質を有効成分とする薬剤
CN121109289A (zh) 高效维持胰岛β细胞身份的胰岛类器官及其制法和应用
ZA200503076B (en) Treatment of diabetes
Class et al. Patent application title: GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF Inventors: Nigel H. Greig (Phoenix, MD, US) Nigel H. Greig (Phoenix, MD, US) Josephine M. Egan (Baltimore, MD, US) Maire Doyle (Baltimore, MD, US) Harold W. Holloway (Middle River, MD, US) Tracy Perry (Baltimore, MD, US)
Elhadd et al. Advances in pharmacotherapy of Type-2 diabetes (Part-2: The incretin mimetics)
MXPA06008394A (en) The combined use of glp-1 agonists and gastrin for regulating blood glucose levels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161101

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161125

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180312